supplement · Tracked item
Obicetrapib
Every recorded take from the experts Cited tracks — each with the exact quote, source, and timestamp.
▲ Strong endorse
2 recommendations across 1 expert · 1 episode
2 endorse
0 nuanced
0 avoid
Who's on the record
-
Attia sees a biologically plausible signal that obicetrapib may attenuate Alzheimer's-related biomarker progression, especially in ApoE4 carriers, though this is speculative.
“this signal is strong enough to justify a dedicated prospective prevention trial
TP▶ 47:30Dosage10 mg daily (as used in Broadway biomarker substudy over 12 months)CaveatsBiomarker study only, no cognitive outcomes yet; very small E4/E4 subgroup (n=29); short 12-month follow-up; mechanism uncertain.Certaintyspeculativerecommendation -
Attia is enthusiastic about obicetrapib, a CETP inhibitor, for lowering LDL-C, ApoB, and Lp(a) on top of maximum lipid-lowering therapy in high-risk cardiovascular patients.
“I haven't been as excited about any drug... as I am with respect to this drug
TP▶ 4:00Dosage10 mg daily added to maximum lipid-lowering therapy (statin ± ezetimibe)CaveatsNot yet FDA-approved in the US; awaiting PREVAIL outcome trial; European approval expected Q4 2026.Certaintyhedgedstrong endorsement